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Abstract
Background: No studies have been conducted on rational drug use among children in Uzbekistan. This study
aimed to analyze drug uses based on pharmaco-epidemiologic (PE) data from Regional Children’s Multi-Profile
Medical Centre (RCMPMC) in Andijan, Uzbekistan. Our study assessed drug usage in children with cardiovascular
(CV) diseases, without intervening in the treatment processes or in the course of the diseases.
Methods: Subjects were 853 children aged 0 to 180 months (median age, 60 months; inter-quartile range, 24–108
months) who were hospitalized in the department of Cardiology and Rheumatology in RCMPMC from January to
December, 2013 and were prescribed one or more drugs during hospitalization. Drugs used for a different disease
or medical condition, given in a different way and/or given in a different dose were analyzed and considered to be
irrational drugs.
Results: The most commonly used medications among 10 drug groups prescribed by the doctors of RCMPMC
were as follows: anti-arrhythmic (aspartic acid - 54.0 %), glycosides (digoxin - 44.0 %), diuretics (furosemide - 34.0 %),
vitamins (ascorbic acid - 25.0 %), steroid anti-inflammatory drugs (prednisolone - 19.0 %), non-steroid anti-inflammatory
drugs (diclofenac - 17.0 %), antibiotics (amoxicillin - 16.0 %), non-steroid anabolic drugs (potassium orotas - 14.0 %) and
angiotensin-converting enzyme inhibitors (captopril - 11.0 %).
Conclusions: The study found that irrational drug schemes were quite frequent among pediatric CV patients and they
are most frequent in children aged 2–3 years and younger.
Keywords: Cardiovascular drugs, Cardio-rheumatologic diseases, Congenital heart diseases, Drug use, Pediatrics
Background
Hospitalized pediatric patients with congenital and ac-
quired heart and rheumatic diseases are prone to influ-
ence by both the advantages and risks of inpatient care.
The risks may be associated with undesirable drug
effects [1] caused by either off-label or irrational drug
prescription. Such attitude to treatment increases the
cost of care, frequency of side effects and the duration
of hospitalization [2, 3].
According to the studies from different countries, 0.15
to 93.6 % of patients are treated with various kinds of
errors, including prescribing, transcribing and administra-
tion [4–6]. Majority of medicines prescribed have not
been studied properly and do not have direct indications
to be used in pediatric practice. Most treatments are de-
cided only by clinical experience and doctors’ own obser-
vations. Evidence from clinical trials is not used. Drug
calculation is disproportioned by using adult doses [7, 8].
Early estimates showed that medical practice based on sci-
entific evidence was as low as 10 to 21 % [9]. The reasons
for insufficient information from pharmacological clinical
trials conducted in pediatric patients are high diversity
among few patients resulting in an absence of statistical
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power, difficulty in obtaining consent from parents, and
lack of resources in pediatric research organizations.
Enough studies were performed to investigate the
prescribing trends in adults [10, 11], whereas pediatri-
cians lack such detailed information on most of the
drugs [12, 13]. Therefore, children are very vulnerable
to possible harmful drug effects, and there are not
enough studies on drug use in children [2].
Drug use can be evaluated retrospectively by analyz-
ing prescriptions called “Drug Utilization Study or Re-
search (DUR)” which is considered as an essential part
of utilization-oriented pharmaco-epidemiology (PE)
[14]. PE assesses drug effects in large heterogeneous
population of patients over a long period of time with-
out intervening into the treatment process and without
affecting the course of the diseases. DUR developed
quickly during the following 30 years [14]. Especially
rapid progress was noticed in Australia, Africa, Latin
America and South and Middle East, and the number
of papers which were published in English increased
from 70 in 1973 to 486 in 2000 [13, 15, 16]. However,
Asian countries, in particular the Central Asia, have no
works in PE until now.
The prevalence of congenital heart diseases (CHD)
was reported as 8 per 1,000 live births in the world be-
tween 1930 and 1990 (0.6 per 1,000 live births −95 %
confidence interval (CI): 0.4 to 0.8 in 1930–1934; 9.1 per
1,000 live births −95 % CI: 9.0 to 9.2 after 1995) [17].
Total CHD prevalence was around 9.3 in 2010 [17].
However, Asia has higher prevalence (9.3 per 1,000 live
births) in comparison to Europe (8.2 per 1,000 live
births) and North America (6.9 per 1,000 live births)
[17]. Annually, 1.35 million children are born with CHD
[17] and it is one of the biggest global health burdens, as
it affects nearly 1 % of live births and reaches $6 billion
in acute care cost alone annually [18]. In Uzbekistan,
10 % of all mortality cases are due to congenital anomal-
ies. Although CHD constitute one third of anomalies,
complete estimates are unavailable because the data is
scarce in Uzbekistan [17, 19]. If no treatment is carried
out, 60 % of children with CHD die within the first 2 years.
The fact is widely recognized that there are more lethal
cases in developing countries [7, 20]. Therefore, it is vital
to organize proper treatment both by surgery and by ra-
tional medication procedures. We carried out utilization-
oriented PE analysis by using DUR to analyze drug use in
a pediatric population hospitalized with congenital and
acquired heart and rheumatic diseases in the department
of Cardiology and Rheumatology in Regional Children’s
Multi-Profile Medical Centre (RCMPMC) in Andijan,
Uzbekistan. Another aim of our study is to contextualize
the need to develop reasonable national estimates of
pediatric in-patients treated with a variety of drugs. The
lack of such estimations in recent times is hampering the
monitoring of hospital drug usage patterns and adverse
drug events associated with a certain drug [21].
Methods
Data for this study were collected from case histories of
all patients who were hospitalized in the department of
Cardiology and Rheumatology of RCMPMC in Andijan,
Uzbekistan from January until December, 2013. The qual-
ity and reliability of data were assured by the joint work of
Andijan State Medical Institute and the department of
Cardiology and Rheumatology of RCMPMC. The hospital
provided all necessary information on demographics, diag-
noses and all procedures that the patients underwent
during the period of hospitalization.
Subjects were children aged 180 months or younger
with congenital and acquired heart and rheumatic dis-
eases and received one or more drugs. All drugs prescribed
to the study subjects were counted and classified as
NSAIDs (non-steroid anti-inflammatory drugs), SAIDs
(steroid anti-inflammatory drugs), vitamins-microelements,
antibiotics (cephalosporins, penicillins, amino glycosides,
macrolides, sulfonamides, lincosamides, fluoroquinolones),
antihistamines, bronchodilators, diuretics, antispasmodic,
CV drugs (including β-adrenergic blocking agents, glyco-
sides, angiotensin-converting enzyme (ACE) inhibitors) and
other drugs such as antivirus, sedative, immune-stimulators
and immune-suppressants. We calculated the minimum
drug dose per kg for each drug category and estimated
whether the drug was used within the approved age range
and with indications for pediatrics (rational). For drugs
without exact data of dose per kilogram, we considered the
age of patients. Demographic and diagnostic variables and
the number of total prescribed drugs were summarized
using frequencies and percentages for categorical variables
and medians and inter-quartile ranges for continuous vari-
ables. All analyses were performed using Statistical Package
for Social Science (SPSS) version 22 (SPSS Inc. Chicago, IL,
USA) and statistical significance was considered at p < 0.05.
Approval was obtained from Ethical Committee of Andi-
jan State Medical Institute on June 1, 2014. The Ethical
Committee agreed that informed consent was not needed
to be taken from patients because no personal data were
recorded.
Results
Table 1 shows drug usage according to selected character-
istics in children hospitalized with congenital and acquired
heart and rheumatic diseases. Our study population was
comprised of patients with diverse diagnostic backgrounds
and treatments. Some patients were treated only by medi-
cation and the others were treated by surgery followed by
medication. Patients with CHD comprised the largest pro-
portion of our study population (frequency, 76.0 %) and
only 18.0 % of the patients underwent operations.
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CV diagnoses are shown in Table 2. Evaluation of the
median age for each group of diagnosis showed that
patients with atrioventricular canal were the youngest
group (median age, 12 months; inter-quartile range, 5–36
months) and patients with rhythm disorders were the
eldest group (median age, 156 months; inter-quartile
range, 132–168 months). Juvenile rheumatoid arthritis
was the most frequent diagnosis in the group of rheumatic
Table 1 Drug use according to selected characteristics in children hospitalized with congenital and acquired heart diseases (n = 853)
Characteristics Irrational drug use
Yes No Total
Number (%) Number (%) Number (%)
Gender
Male 274 (58.2) 197 (41.8) 471 (100)
Female 221 (57.9) 161 (42.1) 382 (100)
Residence
Urban 88 (54.7) 73 (45.3) 161 (100)
Rural 407 (58.8) 285 (41.2) 692 (100)
Age (years)
≤ 1 136 (76.8) 41 (23.2) 177 (100)
2–3 110 (67.1) 54 (32.9) 164 (100)
4–6 100 (50.8) 97 (49.2) 197 (100)
7–11 95 (52.5) 86 (47.5) 181 (100)
12–15 54 (40.3) 80 (59.7) 134 (100)
Length of hospitalization (days)
1–7 205 (50.5) 201 (49.5) 406 (100)
≥ 8 290 (64.9) 157 (35.1) 447 (100)
Diagnosis
Congenital heart diseases treated by surgery + drug therapy
Yes 81 (53.6) 70 (46.4) 151 (100)
No 414 (59.0) 288 (41.0) 702 (100)
Congenital heart diseases treated only by drug therapy
Yes 331 (66.9) 164 (33.1) 495 (100)
No 164 (45.8) 194 (54.2) 358 (100)
Acquired cardiovascular diseases treated by drug therapy
Yes 398 (67.9) 188 (32.1) 586 (100)
No 97 (36.3) 170 (63.7) 267 (100)
Rheumatic diseases treated by drug therapy
Yes 88 (45.1) 107 (54.9) 195 (100)
No 407 (61.9) 251 (38.1) 658 (100)
Weight (kg)
≤ 10 182 (75.5) 59 (24.5) 241 (100)
11–19 166 (56.7) 127 (43.3) 293 (100)
≥ 20 147 (46.1) 172 (53.9) 319 (100)
Number of prescribed drugs
1–4 65 (21.4) 239 (78.6) 304 (100)
5 115 (56.4) 89 (43.6) 204 (100)
6 153 (86.9) 23 (13.1) 176 (100)
7–14 162 (95.9) 7 (4.1) 169 (100)
All subjects 495 (58.0) 358 (42.0) 853 (100)
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diseases with median age of 108 months (inter-quartile
range, 72–144 months). Mesocardia, mitral valve stenosis,
scleroderma, non-rheumatic carditis and recurrent rheum-
atic fever were diagnosed only in 0.1 % of patients hospital-
ized in the department of Cardiology and Rheumatology.
Table 3 shows summarized information about the
groups of 182 drugs which were administered to our study
population. We categorized the drugs prescribed by the
doctors of RCMPMC into 10 groups and examined. Anti-
biotics, vitamins-microelements and CV drugs were pre-
scribed to the majority of patients (62.0, 80.0 and 64.0 %
of all cases) with irrational usage in 88.0, 23.0 and 88.0 %
of prescriptions. NSAIDs, antihistamines and glycosides
were prescribed to around 40.0 % of children. The
irrational usages of these were 85.0, 32.0 and 100 %,
respectively. The following drugs were -prescribed in all
cases irrationally and the percentage of their prescriptions
were as follows: aminoglycosides (7.0 %), sulfonamides
(0.8 %), fluoroquinolones (0.1 %), hydrochlorthiazide
(0.1 %), hydrochlorthiazide + triamteren (1.0 %), β-
adrenergic blocking agents (4.0 %), bendazol (0.1 %), pir-
acetam + cinnarizin (0.5 %) and verapamil (0.1 %). Other
most common medications prescribed irrationally were
diclofenac (prescribed in 99.0 % cases, over-dose in 17.0 %
of patients), prednisolone (96.0 %, over-dose in 19.0 %
patients) and macrolides (96.0 %, over-dose in 12.0 %
prescriptions). Amoxicillin, digoxin and potassium orotas
were irrationally-prescribed in all cases being more than
the required amount per kg. Only aspartic acid was pre-
scribed within normal dose range in all cases.
All diuretics were prescribed for 36.0 % of patients
(Table 3). Hydrochlorothiazide and hydrochlorothia-
zide + triamteren were administered in extra doses in
100 % of cases. CV drugs group included ACE inhibi-
tors (captopril), β-adrenergic blocking agents (propran-
olol), calcium channel blocking agents (verapamil) and
peripheral vasodilators (bendazol and piracetam + cinnari-
zine). ACE inhibitors were prescribed in 12.0 % of pa-
tients, and captopril was ordered irrationally in 64.0 % of
all cases. Propranolol and verapamil were prescribed in
4.0 and 0.1 % of cases. Both drugs were used 100 % in
extra doses. Peripheral vasodilators were used in 0.1 and
0.5 % of all cases. Piracetam + cinnarizine was used 100 %
irrationally in 0.5 % administered cases.
Table 2 Frequency distribution of diagnosis in patients with
congenital and acquired heart diseases (n = 853)
Diagnosis Number (%) Age
Median (IQR)a
Congenital heart diseases 646 (75.7) 36 (12–60)
Acquired cardiovascular diseases 586 (68.7) 36 (12–72)
Rheumatic diseases 195 (22.9) 96 (60–144)
aInter-quartile range in month
Table 3 Prescribed drugs and irrational usage in patients with





Number of patients received
irrational drugs (%)a
NSAIDsb 349 (40.9) 298 (85.4)
Diclofenac 143 (16.8) 142 (99.3)
SAIDsc 201 (23.6) 192 (95.5)
Prednisolone 159 (18.6) 153 (96.2)
Vitamins-
microelements
686 (80.4) 157 (22.9)
Ascorbic acid 215 (25.2) 10 (4.7)
Aspartic acid 461 (54.0) 0
Antibiotics 532 (62.4) 470 (88.3)
Cephalosporins 293 (34.3) 220 (75.1)
Penicillins 234 (27.4) 216 (92.3)
Amoxicillin 134 (15.7) 134 (100)
Aminoglycosides 65 (7.6) 65 (100)
Macrolides 98 (11.5) 94 (95.9)
Sulfonamides 7 (0.8) 7 (100)
Lincosamides 3 (0.4) 2 (66.7)
Fluoroquinolones 1 (0.1) 1 (100)
Antihistamines 379 (44.4) 122 (32.2)
Broncholitics 42 (4.9) 33 (78.6)
Diuretics 310 (36.3) 134 (43.2)
Furosemide 288 (33.8) 115 (39.9)
Hydrochlorothiazide 1 (0.1) 1 (100)
Hydrochlorothiazide
+ triamteren
8 (0.9) 8 (100)
Antispasmodics 32 (3.8) 22 (68.8)
Cardiovascular
drugs
542 (63.5) 477 (88.0)
Glycosides 374 (43.8) 374 (100)
Digoxin 373 (43.7) 373 (100)
ACE inhibitorsd 98 (11.5) 58 (59.2)
Captopril 91 (10.7) 58 (63.7)
β-adrenergic
blocking agents
37 (4.3) 37 (100)
Propranolol 37 (4.3) 37 (100)
Other cardiovascular
drugs
139 (16.3) 71 (51.1)
Bendazol 1 (0.1) 1 (100)
Piracetam +
cinnarizin
4 (0.5) 4 (100)
Verapamil 1 (0.1) 1 (100)
Other drugs 327 (38.3) 221 (67.6)
Potassium orotas 115 (13.5) 115 (100)
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Figure 1a shows frequency distribution of patients re-
ceiving drugs and Figure 1b illustrates the number of pa-
tients who were prescribed the drugs in irrationally high
dose. Out of 853 patients, 358 (42.0 %) were not pre-
scribed irrational drugs (overdose drugs). One drug over-
usage was the most common prescription error (n = 222,
26.0 %) and less than 1 % of patients (n = 6) received the
maximum 6 irrational medications. In our study 6 patients
were prescribed 6 drugs with 4–6 in extra doses, 20 pa-
tients 5 drugs with 2–5 over-dosage and 34 patients 4
drugs with 3–4 extra-dosage.
Number of patients prescribed drugs and percentages
of irrational prescriptions according to clinical and
demographic characteristics are shown in Table 4. In
the age group ≤1 years old, SAIDs, antibiotics, diuretics,
antispasmodics and CV drugs were prescribed signifi-
cantly more often. Their irrational usage was also higher
at the age ≤1 years old in comparison to other age groups.
Though antihistamines were not prescribed in more cases
in this age group, their irrational usage was higher (29 %)
than in older patients. NSAIDs, vitamins-microelements
and diuretics were prescribed in fewer cases over-dose at
the age ≤1 years old compared to other drugs and age
groups. The length of hospitalization was also significantly
associated with irrational prescription: the more days the
patients spent in hospital, the higher is the possibility of
over-dose prescription (especially for the drugs groups of
vitamin-microelements, antispasmodics and other drugs).
Patients whose weight is ≤10 kg also received more drugs
irrationally in comparison to patients in other weight
groups. Another not less significant factor for irrational
prescription is the number of the prescribed drugs. In case
of 7–14 drugs per prescription the irrational usage was
significantly high for SAIDs, vitamins-microelements, an-
tibiotics, bronchodilators, antispasmodics, CV drugs and
the drugs in the group named “other drugs”. .
Discussion
Though there were many reviews of drug use by national
and international authorized organizations country-
specific guidelines for drug use still lack labeling, espe-
cially drugs for children with congenital and acquired
heart diseases. Further more detailed and large scale re-
searches are necessary to minimize the gap between the
availability of drugs and real drug usage in children.
Children are sometimes considered to be “small adults”
[22] or “therapeutic orphans” [23], especially when some
drugs are used for children’s treatment although they
lack data for pediatric efficacy and safety [24].
Fifty eight percent of patients were prescribed over-
dose drugs (irrational) in this study. Our results are not
consistent with a study conducted in other countries in
the Middle East which reported an incidence rate of
prescribing errors from 0.15 to 34.8 %. The reason for ir-
rational prescription may be the tendency of the doctors
of RCMPMC in Andijan to poly-pharmacy that in their
opinion may treat both main diseases and co-morbidities
[4, 5, 7]. Yet, the difference in findings may be due to
different methodology, scale of researches, and sample
size [25-27]. With the increasing complexity of pharma-
cologic interventions with poly-pharmacy [28], the risk
of medication errors may also increase [26]. The per-
centage of prescribed drugs depends on diagnosed con-
ditions that may differ between countries or even
regions [2]. In one study patients taking 10 or more
drugs had nearly 50 % risk of error due to additive effect
of each prescribed medicine at the same time [25]. Our
study found that diclofenac, prednisolone, amoxicillin,
digoxin, furosemide, captopril and potassium orotas
were administered irrationally in 99.3, 96.2, 100, 100,
39.9, 63.7 and 100 % of cases, respectively. Doctors’ be-
havior in prescribing drugs contraindicated for pediatric
use or prescribing more than indicated could be attrib-
uted to their lack of sufficient knowledge [1] for the use
of selected drugs or may be due to their own practice
based perception from observing the positive effects [22]
of such “adult drugs” in children.
Diuretics formed one third of all antihypertensive pre-
scriptions in our study whereas a previous study [21] found
a
b
Fig. 1 Frequency of patients receiving drugs (n = 853). (a) This
figure illustrates frequency distribution of patients prescribed the
drugs (n = 853); (b) This figure illustrates the number of patients
prescribed rational and irrational drugs (n = 853)
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Table 4 Number of patients prescribed drugs and percentages of irrational prescriptions according to clinical and demographic characteristics (n = 853)
Characteristics NSAIDsa SAIDsb Vitamins-microelements Anti-biotics Anti-histamines Broncho-dilators Diuretics Anti-spasmodics Cardiovascular drugs Other drugs
Gender
Male 184 (33) 111 (23) 371 (19) 303 (58) 202 (15) 21 (4) 168 (17) 18 (3) 299 (55) 175 (24)
Female 165 (37) 90 (23) 315 (18) 229 (52) 177 (13) 21 (4) 142 (15) 14 (2) 243 (57) 152 (28)
Residence
Urban 70 (39) 32 (19) 122 (14) 102 (55) 86 (14) 10 (4) 42 (10) 5 (1) 84 (49) 62 (27)
Rural 279 (34) 169 (23) 564 (19) 430 (55) 293 (15) 32 (4) 268 (17) 27 (3) 458 (58) 265 (26)
Age (years)
≤ 1 54 (18) 93 (50) 137 (7) 162 (78) 71 (29) 15 (7) 83 (9) 17 (6) 140 (76) 65 (25)
2–3 64 (32) 48 (28) 140 (19) 123 (68) 64 (12) 15 (7) 78 (16) 4 (2) 130 (71) 57 (21)
4–6 85 (38) 16 (7) 167 (21) 115 (51) 101 (19) 8 (4) 76 (16) 1 (1) 129 (56) 61 (22)
7–11 80 (42) 30 (17) 141 (23) 87 (44) 81 (5) 4 (2) 50 (22) 3 (2) 92 (41) 80 (32)
12–15 66 (49) 14 (10) 101 (22) 45 (30) 62 (3) 0 23 (16) 7 (2) 51 (31) 64 (30)
Length of hospitalization (days)
1–7 150 (33) 75 (18) 326 (17) 253 (54) 174 (15) 15 (3) 153 (14) 8 (1) 266 (59) 136 (22)
≥ 8 199 (37) 126 (27) 360 (20) 279 (56) 205 (14) 27 (5) 157 (17) 24 (4) 276 (54) 191 (30)
Diagnosis
Congenital heart diseases
Surgical + medical 29 (11) 23 (14) 121 (24) 95 (58) 58 (15) 7 (4) 68 (19) 7 (3) 102 (54) 72 (34)
Medical 164 (26) 121 (23) 432 (20) 333 (59) 199 (20) 30 (5) 233 (20) 14 (2) 427 (78) 186 (26)
Acquired cardiovascular diseases
Medical 191 (25) 158 (26) 520 (20) 394 (59) 218 (16) 34 (4) 294 (22) 27 (3) 503 (77) 243 (29)
Rheumatic diseases
Medical 126 (64) 39 (19) 125 (15) 90 (42) 112 (7) 3 (1) 23 (5) 5 (2) 48 (22) 76 (27)
Weight (kg)
≤ 10 72 (18) 117 (46) 191 (10) 215 (76) 95 (28) 21 (6) 111 (9) 17 (5) 196 (77) 83 (23)
11–19 130 (39) 45 (15) 249 (21) 179 (57) 134 (14) 18 (6) 126 (15) 4 (1) 202 (60) 101 (22)
≥ 20 147 (44) 39 (12) 246 (23) 138 (38) 150 (4) 3 (1) 73 (21) 11 (2) 144 (37) 143 (32)
Number of prescribed drugs















Table 4 Number of patients prescribed drugs and percentages of irrational prescriptions according to clinical and demographic characteristics (n = 853) (Continued)
5 85 (36) 29 (14) 185 (22) 115 (46) 82 (14) 7 (3) 86 (19) 2 (1) 153 (66) 75 (25)
6 62 (29) 47 (26) 158 (21) 133 (68) 95 (21) 8 (3) 88 (24) 6 (3) 146 (75) 71 (31)
7–14 78 (33) 93 (53) 154 (26) 145 (81) 83 (20) 20 (10) 95 (18) 21 (8) 131 (69) 104 (45)
Each value in parenthesis represents the percentage of patients with irrational drug prescriptions in each subgroup. Values in bold type indicate a significant difference (Chi-square test, P < 0.01) among the

















that the combination of diuretics and CV agents was
10 and 90 %, respectively. Doctors of RCMPMC in
Andijan may have used diuretics and CV agents for an-
tihypertensive effect. Hydrochlorthiazide and hydro-
chlorthiazide + triamteren (diuretics), propranolol (β-
adrenergic blockers), verapamil (calcium channel blockers)
and piracetam+ cinnarizine (peripheral vasodilators) were
administered in 100 % of cases irrationally because there
are no indications for their administration at children’s age.
These drugs might be considered the most appropriate
ones by the doctors of RCMPMC in Andijan in respect of
the severity of the disease.
Our analysis showed that several drugs pertaining to
NSAIDs and antibiotics were unnecessarily combined in
the treatment. However, SAIDs were not misused so
much. Glycosides and antispasmodics were prescribed
only by 1 type per person, whereas other CV drugs like β-
adrenergic blocking agents, calcium channel blockers and
peripheral vasodilators were more likely to be prescribed
all together per one patient. Our literature review did not
find relevant result in other studies conducted previously
[7, 26]. In our study, significant amount of irrational pre-
scriptions were among antibiotics, glycosides, NSAIDs,
SAIDs and β-adrenergic blocking agents. The results of
our study were consistent with those of the previous ones
[2, 26]. The patients younger than 2-3 years old had the
highest number of prescriptions in all groups of drugs
(Table 4). The most vulnerable group were children aged
1–2 years and younger in previous studies [7, 26], which is
consistent with our finding.
Treatment of congenital and acquired heart diseases by
surgery or interventional procedures is always expensive
and this may be one of main barriers on the way to
achieving good cardiac care outcome [26]. Therefore, drug
therapy may be an effective way to reach this aim, but will
require improvement of treating schemes with minimal
errors and maximal benefit for health. Novel approaches
to building evidence-based treatment schemes, which
generate sufficient information in real-time through retro-
spective analyses experience, may turn out to be a quite
vital complement to clinical trials and classic cohort
studies.
The following steps are suggested to bring improvement
in evidence-based treatment practice in Uzbekistan. First,
the interventional role of pharmacologists should be in-
creased in decision making process for treatment of pa-
tients in each department by appointing responsible
person from pharmacological background for pharmaceut-
ical affairs management. Second, retrospective analyses
should be conducted regularly (at least once per 2 years) to
identify the current errors and their reasons and to evalu-
ate the degree of improvement in response to suggested
interventions. Third, medical personnel should be re-
educated and it is necessary to make sure that they have
up-to-date knowledge in line with all new national and
international standard guidelines, dissemination of com-
puterized information, and continuing pharmacological
education.
Our study has some limitations. In this study we consid-
ered irrational prescription only from view point of weight
and age. However, route of administration, performance
of injections, and drug intake by patients that are consid-
ered to be other types of medication errors were not in-
cluded in the study. We studied the PE of CV medications
in only one department within one RCMPMC out of all
existing medical centers in Uzbekistan. Although the re-
sults of this study may not be generalized to the situation
in the whole country, they can highlight areas for further
investigations of the same problem in all hospitals.
Conclusion
In conclusion, The study found that irrational drug
schemes were quite frequent among pediatric CV patients
and they are most frequent in children aged 2–3 years and
younger.
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